

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6256]

Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
CompanyJohnson and Johnson (amivantamab, lazertinib)Patient/carer groups	 General All Wales Therapeutics and Toxicology Centre Allied Health Professionals Federation Board of Community Health Councils in
 Asthma and Lung UK Black Health Agency for Equality Cancer Black Care Cancer Equality Cancer52 EGFR Positive UK Helen Rollason Cancer Charity Independent Cancer Patients Voice Macmillan Cancer Support Maggie's Centres Marie Curie Oncogene-Driven Lung Cancer Patient Alliance Roy Castle Lung Cancer Foundation 	 Wales British National Formulary Care Quality Commission Department of Health – Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Confederation Scottish Medicines Consortium Welsh Government Welsh Health Specialised Services Committee
 Ruth Strauss Foundation South Asian Health Foundation Specialised Healthcare Alliance Tenovus Cancer Care UK Lung Cancer Coalition Healthcare professional groups Association of Anaesthetists Association of Cancer Physicians Association of Respiratory Nurse Specialists Association of Surgeons of Great Britain and Ireland British Geriatrics Society British Institute of Radiology 	 Comparator companies Amarox (erlotinib) AstraZeneca (gefitinib, osimertinib) Boehringer Ingelheim (afatinib) Cipla EU (gefitinib) Genus Pharmaceuticals (gefitinib) Glenmark Pharmaceutical (erlotinib) Mylan (erlotinib) Pfizer (dacomitinib) Roche (erlotinib) Sandoz (erlotinib, gefitinib) Zentiva (erlotinib) Relevant research groups
British Oncology Pharmacy Association	Cochrane Lung Cancer GroupCochrane UK

Stakeholder list for the evaluation of amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6256]



Provisional Consultees Provisional Commentators (no right to submit or appeal) British Psychosocial Oncology Society Genomics England British Society of Interventional Institute of Cancer Research Radiology MRC Clinical Trials Unit **British Thoracic Oncology Group** National Institute for Health Research **British Thoracic Society British Transplantation Society** Associated Public Health groups **Public Health Wales** Cancer Research UK Lung Cancer and Mesothelioma UK Health Security Agency Clinical Expert Group Lung Cancer Nursing UK National Heart and Lung Institute NHS Blood and Transplant Primary Care Respiratory Society Royal College of Anaesthetists Royal College of General Practitioners Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal College of Radiologists Royal College of Surgeons Royal Pharmaceutical Society Royal Society of Medicine Society and College of Radiographers **UK Clinical Pharmacy Association UK Oncology Nursing Society Others** Department of Health and Social Care NHS England


NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Stakeholder list for the evaluation of amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6256]

Issue date: October 2024



Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.